Article (Scientific journals)
Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial.
Reginster, Jean-Yves; Badurski, J; Bellamy, N et al.
2013In Annals of the Rheumatic Diseases, 72 (2), p. 179-86
Peer Reviewed verified by ORBi
 

Files


Full Text
Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis.pdf
Publisher postprint (2.7 MB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Osteoarthritis; Knee Osteoarthritis; Aged; Antirheumatic Agents/therapeutic use; Double-Blind Method; Female; Humans; Male; Middle Aged; Organometallic Compounds/therapeutic use; Osteoarthritis, Knee/drug therapy/radiography; Thiophenes/therapeutic use; Treatment Outcome
Abstract :
[en] BACKGROUND: Strontium ranelate is currently used for osteoporosis. The international, double-blind, randomised, placebo-controlled Strontium ranelate Efficacy in Knee OsteoarthrItis triAl evaluated its effect on radiological progression of knee osteoarthritis. METHODS: Patients with knee osteoarthritis (Kellgren and Lawrence grade 2 or 3, and joint space width (JSW) 2.5-5 mm) were randomly allocated to strontium ranelate 1 g/day (n=558), 2 g/day (n=566) or placebo (n=559). The primary endpoint was radiographical change in JSW (medial tibiofemoral compartment) over 3 years versus placebo. Secondary endpoints included radiological progression, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score, and knee pain. The trial is registered (ISRCTN41323372). RESULTS: The intention-to-treat population included 1371 patients. Treatment with strontium ranelate was associated with smaller degradations in JSW than placebo (1 g/day: -0.23 (SD 0.56) mm; 2 g/day: -0.27 (SD 0.63) mm; placebo: -0.37 (SD 0.59) mm); treatment-placebo differences were 0.14 (SE 0.04), 95% CI 0.05 to 0.23, p<0.001 for 1 g/day and 0.10 (SE 0.04), 95% CI 0.02 to 0.19, p=0.018 for 2 g/day. Fewer radiological progressors were observed with strontium ranelate (p<0.001 and p=0.012 for 1 and 2 g/day). There were greater reductions in total WOMAC score (p=0.045), pain subscore (p=0.028), physical function subscore (p=0.099) and knee pain (p=0.065) with strontium ranelate 2 g/day. Strontium ranelate was well tolerated. CONCLUSIONS: Treatment with strontium ranelate 1 and 2 g/day is associated with a significant effect on structure in patients with knee osteoarthritis, and a beneficial effect on symptoms for strontium ranelate 2 g/day.
Disciplines :
General & internal medicine
Author, co-author :
Reginster, Jean-Yves  ;  Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Badurski, J
Bellamy, N
Bensen, W
Chapurlat, R
Chevalier, X
Christiansen, C
Genant, H
Navarro, F
Sambrook, PN
Spector, TD
Cooper, C
Language :
English
Title :
Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial.
Publication date :
2013
Journal title :
Annals of the Rheumatic Diseases
ISSN :
0003-4967
eISSN :
1468-2060
Publisher :
BMJ Group, London, United Kingdom
Volume :
72
Issue :
2
Pages :
179-86
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 09 April 2013

Statistics


Number of views
77 (11 by ULiège)
Number of downloads
2 (2 by ULiège)

Scopus citations®
 
237
Scopus citations®
without self-citations
211
OpenCitations
 
209

Bibliography


Similar publications



Contact ORBi